Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

36 ANAKINRA
ANAKINRA
Synonym: IL-1RA
Trade name: Kineret (Amgen)
Indications: Rheumatoid arthritis
Category: Disease-modulating antirheumatoid drug; Interleukin-
1 receptor antagonist (IL- IRa)
Half-life: 4–6 hours
Clinically important, potentially hazardous interactions
with: etanercept
Reactions
Skin
Cellulitis
(2004): Riente L, Reumatismo 2004 Jan–Mar 56(1 Suppl 1), 74
Lichenoid eruption
(2005): Vila AT+, Br J Dermatol 153(2), 417
Other
Hypersensitivity
Infections (40%)
(2004): Prescrire Int 13(70), 43
(2004): Turesson C+, J Rheumatol 31(9), 1876
(2003): Fleischmann RM+, Arthritis Rheum 48(4), 927 (2.1%)
(2003): Kary S+, Int J Clin Pract 57(3), 231
Injection-site ecchymoses
Injection-site edema
(2005): Vila AT+, Br J Dermatol 153(2), 417
Injection-site erythema
(2005): Vila AT+, Br J Dermatol 153(2), 417
Injection-site inflammation
Injection-site pain
Injection-site reactions (sic) (71%)
(2006): den Broeder AA+, Ann Rheum Dis 65(6), 760 (36%)
(2006): Fleischmann RM+, Ann Rheum Dis 65(8), 1006
(2005): Haibel H+, Ann Rheum Dis 64(2), 296
(2005): Vila AT+, Br J Dermatol 153(2), 417
(2004): Prescrire Int 13(70), 43 (75%)
(2004): Clark W+, Health Technol Assess 8(18), iii–iv, ix–x, 1
(2004): Cohen SB+, Ann Rheum Dis 63(9), 1062
(2004): Furst DE, Clin Ther 26(12), 1960
(2004): Riente L, Reumatismo 2004 Jan–Mar 56(1 Suppl 1), 74
(71%)
(2004): Schiff MH, Drugs 64(22), 2493
(2003): Fleischmann RM, Rheumatology (Oxford) 42(Suppl
2), ii29
(2003): Kary S+, Int J Clin Pract 57(3), 231
(2003): Langer HE+, Int J Clin Pharmacol Res 23(4), 119
(2002): Calabrese LH, Ann Pharmacother 36(7), 1204
(2002): Cohen S+, Arthritis Rheum 46(3), 614
(2001): Bresnihan B, Semin Arthritis Rheum 30(5 Suppl 2), 17
(2001): Garces K, Issues Emerg Health Technol May(16), 1
(1998): Bresnihan B+, Arthritis Rheum 41(12), 2196
Upper respiratory infection (4%)
(2006): Fleischmann RM+, Ann Rheum Dis 65(8), 1006
ANASTROZOLE
Trade name: Arimidex (AstraZeneca)
Indications: Breast carcinoma (localized-advanced or metastatic)
Category: Aromatase inhibitor
Half-life: 50 hours
Reactions
Skin
Diaphoresis
(1997): Jonat W, Oncology 54 (Suppl 2), 15
Peripheral edema (10.1%)
Pruritus (2–5%)
Rash (sic) (7.5%)
Shivering
Mucosal
Vaginal dryness (1.7%)
Xerostomia
Hair
Hair – alopecia (2–5%)
Other
Chills
Cough (10.9%)
Hepatotoxicity
(2007): de la Cruz L+, Lancet 369(9555), 23 (with geftinib)
(2006): Carlini P+, J Clin Oncol 24(35), e60
(2006): Zapata E+, Eur J Gastroenterol Hepatol 18(11), 1233
Hot flashes (26.5%)
(2005): Prescrire Int 14(76), 43 (30%)
(2003): Baum M+, Cancer 98(9), 1802
(2003): del Carmen MG+, Gynecol Oncol 91(3), 596
(2002): Buzdar AU, Expert Rev Anticancer Ther 2(6), 623
(1998): Higa GM+, Am J Health 55(5), 445
Infections (2–5%)
Myalgia/Myositis/Myopathy/Myotoxicity (2–5%)
Pain (13.8%)
(1998): Higa GM+, Am J Health 55(5), 445
Thrombophlebitis (2–5%)
Tumor pain (>5%)
ANDROSTENEDIONE
Scientific names: 4-androstene-3,17-dione; Androst-4-ene-3,17dione
Family: N/A
Trade and other common names: Andro; Androstene
Category: Aromatase inhibitor
Purported indications and other uses: Enhanced athletic
performance, increased energy, to keep red blood cells healthy
Half-life: N/A
Reactions
Skin
Acne
(1999): Pheatt N, Sports Supplements. Pharmacist’s Letter 99, 1
(1998): Med Lett Drugs Ther 40, 105
Adverse effects (sic)
(2003): Juhn M, Sports Med 33(12), 921
(2003): Kicman AT+, Clin Chem 49(1), 167
(2002): Leder BZ+, J Clin Endocrinol Metab 87(12), 5449